Literature DB >> 23389967

Heat-treated emulsions with cross-linking bovine serum albumin interfacial films and different dextran surfaces: effect of paclitaxel delivery.

Jianing Qi1, Chong Huang, Fen He, Ping Yao.   

Abstract

In this study, a type of biocompatible and biodegradable oil-in-water emulsion for hydrophobic drug delivery was evaluated in vitro and in vivo. Bovine serum albumin (BSA)-dextran conjugates with different dextran molecular weights and different conjugation degrees were used as the emulsifier and stabilizer. Paclitaxel (PTX), a hydrophobic antitumor drug, was effectively loaded inside the oil droplets via high-pressure homogenization. The emulsions were heated at 90°C for 1 h to eliminate the anaphylaxis of BSA. By virtue of the cross-linked BSA films at the oil-water interfaces produced by the heat treatment and the hydrophilic dextran surfaces, the emulsions are stable in blood serum, as well as stable against long-term storage. In vitro cytotoxicity study verifies that the unloaded emulsions are biocompatible and the PTX-loaded emulsions have similar antitumor activity as PTX solution. In vivo investigation of murine ascites hepatoma H22-tumor-bearing mice demonstrates that the PTX-loaded emulsion with shorter and denser dextran surface has better tumor inhibition and survivability efficacy than the commercial PTX injection.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389967     DOI: 10.1002/jps.23468

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Comparison of Different Crosslinking Methods for Preparation of Docetaxel-loaded Albumin Nanoparticles.

Authors:  Hassan Niknejad; Raziyeh Mahmoudzadeh
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

2.  Protamine and BSA-dextran complex emulsion improves oral bioavailability and anti-tumor efficacy of paclitaxel.

Authors:  Guangrui Xu; Xiaoyan Bao; Ping Yao
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.